Olema Pharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by Olema Pharmaceuticals, Inc. of its common stock for up to an aggregate amount of $100 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “OLMA.”
Olema is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next generation targeted therapies for women’s cancers. Olema is headquartered in San Francisco, California.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Paula Gergen and Charlie Lian. The intellectual property team included partner David R. Bauer and associates S. Dream Montgomery and Shreya R. Kundur. The tax team included partner Michael Mollerus and associates Tyler Scheiner and Michael Mirabella. Members of the Davis Polk team are based in the Northern California and New York offices.